keyword
MENU ▼
Read by QxMD icon Read
search

abaloparatide

keyword
https://www.readbyqxmd.com/read/29727238/treatment-of-osteoporosis-whom-how-and-for-how-long
#1
Anastasia D Dede, Margaret Callan
Identification of patients at risk for fragility fractures is the first important step in the management of osteoporosis. Bisphosphonates have been the mainstay of treatment for decades, whereas denosumab and selective oestrogen receptor modulators are other available licensed antiresorptive drugs. Currently teriparatide is the only approved anabolic agent in Europe, while abaloparatide and romosozumab are awaiting approval and might be available in the near future. For bisphosphonates, current guidance suggests an initial treatment course of 3-5 years and more prolonged treatment should be pursued in patients with higher fracture risk...
May 2, 2018: British Journal of Hospital Medicine
https://www.readbyqxmd.com/read/29725706/abaloparatide-exerts-bone-anabolic-effects-with-less-stimulation-of-bone-resorption-related-factors-a-comparison-with-teriparatide
#2
Akito Makino, Hideko Takagi, Yoshimasa Takahashi, Naoki Hase, Hiroyuki Sugiyama, Kei Yamana, Tsunefumi Kobayashi
Abaloparatide (ABL) is a novel synthetic peptide analog of parathyroid hormone-related protein. In previous reports, intermittent ABL administration showed robust bone mineral density (BMD) increase and reduced the incidence of fractures in patients with osteoporosis, while its calcemic effect was reduced, as compared with teriparatide (TPTD), a parathyroid hormone N-terminal fragment. The present study aimed to elucidate the effects of ABL on bone anabolism and bone turnover as compared with TPTD. In ovariectomized (OVX) rats, ABL increased the bone strength and BMD of lumbar spine by intermittent administration similar to TPTD...
May 3, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29627891/anabolic-agents-what-is-beyond-osteoporosis
#3
REVIEW
Y Liu, A E Levack, E Marty, O Or, B P Samuels, M Redko, J M Lane
Osteoporosis is a common skeletal disorder characterized by low bone mass, which leads to reduced bone strength and an increased risk of fractures. Anabolic agents have been shown to improve bone mass and decrease fracture risk in osteoporosis patients by directly stimulating osteoblasts to produce new bone. Currently, two anabolic agents are available in the USA: recombinantly produced teriparatide (TPTD), which is the fully active (1-34) amino active sequence of human parathyroid hormone (PTH), and abaloparatide (APTD), a synthetic analog of parathyroid hormone-related peptide (PTHrP)...
April 7, 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29621030/long-term-treatment-strategies-for-postmenopausal-osteoporosis
#4
Felicia Cosman
PURPOSE OF REVIEW: Osteoporosis guidelines do not usually provide specific recommendations regarding what medication is most appropriate for individual patients. Generic oral bisphosphonates are often considered first-line treatment for osteoporosis, but treatment duration is limited, based on potential long-term safety concerns, and there is no consensus about what to do after 5 years. There are no recommendations concerning long-term management of osteoporosis over 30 or more years of postmenopausal life...
April 4, 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29546647/bone-best-papers-of-the-year-2017
#5
REVIEW
Michaël R Laurent
An overview of selected papers related to bone published in 2017 is provided. PURPOSE: This paper accompanies a lecture at the 2018 Belgian Bone Club annual Clinical Update Symposium held in Brussels on January 20th, discussing the best papers (in the opinion of the author) published in the previous year. METHODS: A PubMed search using the keyword "bone" and articles published in 2017. RESULTS: Hot topics include screening for osteoporosis, novel anabolic drugs such as romosozumab and abaloparatide for osteoporosis and rare metabolic bone diseases, as well as long-term efficacy of denosumab and possible risk of multiple vertebral fractures following its discontinuation...
March 15, 2018: Archives of Osteoporosis
https://www.readbyqxmd.com/read/29462094/effects-of-abaloparatide-on-bone-mineral-density-and-risk-of-fracture-in-postmenopausal-women-aged-80-years-or-older-with-osteoporosis
#6
Michael R McClung, Nicholas C Harvey, Lorraine A Fitzpatrick, Paul D Miller, Gary Hattersley, Yamei Wang, Felicia Cosman
OBJECTIVE: Advanced age is an important risk factor for fracture. The Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) trial showed that subcutaneous abaloparatide increased bone mineral density (BMD) and reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. This study describes the effects of abaloparatide in the subgroup of women aged 80 or more years in ACTIVE. METHODS: Post hoc analyses of BMD and fracture incidence in this subgroup of women who received abaloparatide or placebo in the 18-month, phase 3, double-blind, randomized controlled ACTIVE trial...
February 16, 2018: Menopause: the Journal of the North American Menopause Society
https://www.readbyqxmd.com/read/29383409/correction-to-geography-of-fracture-incidence-in-postmenopausal-women-with-osteoporosis-treated-with-abaloparatide
#7
Michael R McClung, Gregory C Williams, Gary Hattersley, Lorraine A Fitzpatrick, Yamei Wang, Paul D Miller
The article Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide, written by Michael R. McClung, Gregory C. Williams, Gary Hattersley, Lorraine A. Fitzpatrick, Yamei Wang, Paul D. Miller, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 28 December 2017 without open access.
January 31, 2018: Calcified Tissue International
https://www.readbyqxmd.com/read/29290341/safinamide-mesylate-brodalumab-guselkumab-and-abaloparatide
#8
Daniel A Hussar, Mariya Kotova
No abstract text is available yet for this article.
January 2018: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/29285549/geography-of-fracture-incidence-in-postmenopausal-women-with-osteoporosis-treated-with-abaloparatide
#9
Michael R McClung, Gregory C Williams, Gary Hattersley, Lorraine A Fitzpatrick, Yamei Wang, Paul D Miller
Geographic heterogeneity has been observed in fracture risk and efficacy of therapeutic intervention in postmenopausal osteoporosis. The objectives of these analyses were to assess across geographic and ethnic subgroups the heterogeneity of fracture incidence and baseline risk, and consistency of effect of abaloparatide-SC vs placebo on fracture risk reduction in the 18-month, phase 3, multinational, ACTIVE randomized controlled trial. Prespecified exploratory analyses of geographic subgroups (North America, South America, Europe, Asia) and post hoc analyses of ethnic subgroups (Hispanic or Latino, other) of postmenopausal women with osteoporosis enrolled in the abaloparatide-SC and placebo cohorts (n = 1645) were performed...
December 28, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/29279435/-drugs-for-osteoporosis
#10
Seiji Fukumoto
Many important results concerning several drugs for osteoporosis have been presented in ASBMR 2017 meeting. Longer use of denosumab for up to 10 years was shown to induce lower risk of fractures. In addition, antiresorptives were shown to be useful after abaloparatide or romosozumab. Now that several important drugs have been already developed for osteoporosis, research and drug development for other musculoskeletal organs than bone are necessary.
2018: Clinical Calcium
https://www.readbyqxmd.com/read/29260289/abaloparatide-a-novel-pth-receptor-agonist-increased-bone-mass-and-strength-in-ovariectomized-cynomolgus-monkeys-by-increasing-bone-formation-without-increasing-bone-resorption
#11
N Doyle, A Varela, S Haile, R Guldberg, P J Kostenuik, M S Ominsky, S Y Smith, G Hattersley
Abaloparatide, a novel PTH1 receptor agonist, increased bone formation in osteopenic ovariectomized cynomolgus monkeys while increasing cortical and trabecular bone mass. Abaloparatide increased bone strength and maintained or enhanced bone mass-strength relationships, indicating preserved or improved bone quality. INTRODUCTION: Abaloparatide is a selective PTH1R activator that is approved for the treatment of postmenopausal osteoporosis. The effects of 16 months of abaloparatide administration on bone formation, resorption, density, and strength were assessed in adult ovariectomized (OVX) cynomolgus monkeys (cynos)...
March 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29251010/effect-of-a-sequential-treatment-combining-abaloparatide-and-alendronate-for-the-management-of-postmenopausal-osteoporosis
#12
J Y Reginster, Nasser Al Daghri, Jean-Marc Kaufman, Olivier Bruyère
The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 µg/day) (ABL) for 18 months followed by 6 months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with an osteoanabolic agent. The ABL/ALN sequence resulted in greater bone mineral density gains at all skeletal sites and in a reduction of vertebral, non-vertebral, major and clinical fractures compared to what is observed after 18 months of placebo followed by 6 months of ALN...
February 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29241341/abaloparatide-review-of-a-next-generation-parathyroid-hormone-agonist
#13
Eric G Boyce, Yvonne Mai, Christopher Pham
OBJECTIVE: To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis. DATA SOURCES: PubMed (1966 to October 2017), Clinicaltrials.gov (October 2017), and Scopus (1970 to October 2017) were searched using abaloparatide, Tymlos, BA058, PTHrP 1-34 analog, and parathyroid hormone-related peptide 1-34 analog. STUDY SELECTION AND DATA EXTRACTION: Human studies published in peer-reviewed publications in English were the primary sources for efficacy, safety, and economic data...
May 2018: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29167971/abaloparatide-sc-improves-trabecular-microarchitecture-as-assessed-by-trabecular-bone-score-tbs-a-24-week-randomized-clinical-trial
#14
J P Bilezikian, G Hattersley, L A Fitzpatrick, A G Harris, E Shevroja, K Banks, B Z Leder, J R Zanchetta, D Hans
In a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to one of three different doses of abaloparatide-SC, subcutaneous teriparatide, or placebo for 24 weeks, abaloparatide-SC resulted in improvements in skeletal microarchitecture as measured by the trabecular bone score. INTRODUCTION: Subcutaneous abaloparatide (abaloparatide-SC) increases total hip and lumbar spine bone mineral density and reduces vertebral and non-vertebral fractures. In this study, we analyzed the extent to which abaloparatide-SC improves skeletal microarchitecture, assessed indirectly by trabecular bone score (TBS)...
February 2018: Osteoporosis International
https://www.readbyqxmd.com/read/29113980/management-of-endocrine-disease-novel-anabolic-treatments-for-osteoporosis
#15
REVIEW
Ernesto Canalis
Skeletal anabolic agents enhance bone formation, which is determined by the number and function of osteoblasts. Signals that influence the differentiation and function of cells of the osteoblast lineage play a role in the mechanism of action of anabolic agents in the skeleton. Wnts induce the differentiation of mesenchymal stem cells toward osteoblasts, and insulin-like growth factor I (IGF-I) enhances the function of mature osteoblasts. The activity of Wnt and IGF-I is controlled by proteins that bind to the growth factor or to its receptors...
February 2018: European Journal of Endocrinology
https://www.readbyqxmd.com/read/29048260/abaloparatide-comparator-trial-in-vertebral-endpoints-active-confirms-that-abaloparatide-is-a-valuable-addition-to-the-armamentarium-against-osteoporosis
#16
Jean-Yves Reginster, Nasser Mohammad Al Daghri, Olivier Bruyere
The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator. The results of the study suggest that ABL increases bone mineral density more than TPD and reduces major osteoporotic fractures to a greater extent than TPD with a more rapid onset of action...
December 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28914969/autocrine-and-paracrine-regulation-of-the-murine-skeleton-by-osteocyte-derived-parathyroid-hormone-related-protein
#17
Niloufar Ansari, Patricia Wm Ho, Blessing Crimeen-Irwin, Ingrid J Poulton, Athena R Brunt, Mark R Forwood, Paola Divieti Pajevic, Jonathan H Gooi, T John Martin, Natalie A Sims
Parathyroid hormone-related protein (PTHrP) and parathyroid hormone (PTH) have N-terminal domains that bind a common receptor, PTHR1. N-terminal PTH (teriparatide) and now a modified N-terminal PTHrP (abaloparatide) are US Food and Drug Administration (FDA)-approved therapies for osteoporosis. In physiology, PTHrP does not normally circulate at significant levels, but acts locally, and osteocytes, cells residing within the bone matrix, express both PTHrP and the PTHR1. Because PTHR1 in osteocytes is required for normal bone resorption, we determined how osteocyte-derived PTHrP influences the skeleton...
January 2018: Journal of Bone and Mineral Research: the Official Journal of the American Society for Bone and Mineral Research
https://www.readbyqxmd.com/read/28836858/investigational-anabolic-agents-for-the-treatment-of-osteoporosis-an-update-on-recent-developments
#18
REVIEW
Anastasia D Dede, Polyzois Makras, Athanasios D Anastasilakis
Teriparatide, a PTH analogue, was the first anabolic agent to be approved for the treatment of osteoporosis in 2002. Abaloparatide was also recently approved by the FDA. The need for other anabolic agents is still unmet. Areas covered: In this review, we discuss target molecules and recent advances in the field of anabolic therapy for osteoporosis. PTH and PTHrP analogues binding to the PTH receptor and different routes of administration of teriparatide to avoid the burden of daily subcutaneous injections are discussed...
October 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28780668/new-anabolic-therapies-for-osteoporosis
#19
REVIEW
Salvatore Minisola, Cristiana Cipriani, Marco Occhiuto, Jessica Pepe
Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of bone tissue, leading to increased bone fragility that results in fractures. Pharmacological therapy is aimed at decreasing the risk of fracture, mainly correcting the imbalance between bone resorption and formation at the level of bone remodeling units. Anabolic therapy has the capability to increase bone mass to a greater extent than traditional antiresorptive agents. The only currently available drug licensed is parathyroid hormone 1-34 (teriparatide); new drugs are on the horizon, targeting the stimulation of bone formation, and therefore improving bone mass, structure and ultimately skeletal strength...
October 2017: Internal and Emergency Medicine
https://www.readbyqxmd.com/read/28756709/emerging-anabolic-agents-in-the-treatment-of-osteoporosis
#20
REVIEW
Christina Lovato, E Michael Lewiecki
Osteoporosis is a common skeletal disease with serious consequences due to osteoporotic fractures and high costs to society for post-fracture care. Most patients at high risk for fracture are not receiving care to reduce fracture risk. The osteoporosis treatment gap has reached crisis proportions. Strategies to reduce the treatment gap include systematic methods for identifying and treating high risk patients, better education of patients and healthcare providers, better use of currently available drugs, and development of new drugs to treat osteoporosis...
September 2017: Expert Opinion on Emerging Drugs
keyword
keyword
59600
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"